ORGANIZATION OF PHARMACEUTICAL CARE FOR CARDIAC RHYTHM DISORDERS

2025

APRIL

NEW RENAISSANCE

INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE

VOLUME 2

|

ISSUE 4

251

ORGANIZATION OF PHARMACEUTICAL CARE FOR CARDIAC RHYTHM

DISORDERS

Turayev Kh.N.

Ziyadullayev Sh.X.

https://doi.org/10.5281/zenodo.15232161

Relevance of the problem:

This extensive study investigates antithrombotic therapy

optimization for patients with cardiac rhythm disorders (CRDs), with a specific focus on atrial

fibrillation (AF), supraventricular, and ventricular arrhythmias, frequently accompanied by

ischemic heart disease. Conducted from 2020 to 2023 across various cardiology departments in

Uzbekistan, the study evaluated 250 patients to examine their adherence to oral anticoagulant

(OAC) therapy, the potential of platelet microvesicles (PMVs) as biomarkers for thromboembolic

risk, and the alignment of clinical practices with international antithrombotic guidelines.

Research methods and materials:

Findings underscore significant challenges in

treatment adherence, with only 43.1% of patients consistently following prescribed OAC therapy.

Factors such as high therapy costs, limited patient awareness of the therapy’s benefits, and

perceived lack of efficacy contributed to substantial drop-out rates at six and twelve months, even

after educational interventions. This highlights the need for sustained, multifaceted adherence

support. The study also reveals a strong correlation between elevated PMV levels and increased

thromboembolic risk in CRD patients, underscoring the potential of PMVs as predictive

biomarkers. Statistical analyses, including multivariate regression and ROC analysis,

demonstrated that PMVs could serve as practical, accessible tools for routinely assessing

thromboembolic risk, enabling early intervention for high-risk patients.

Results:

Based on these insights, the study recommends establishing a national registry for

CRDs in Uzbekistan, enabling comprehensive tracking of patient outcomes, treatment adherence,

and real-world applications of clinical guidelines. Such a registry would facilitate data-driven

improvements in patient management practices and provide an invaluable resource for future

research. Additional recommendations emphasize the implementation of structured, ongoing

patient education programs to enhance understanding and adherence to OAC therapy. By

continuously educating patients on the importance of adherence, these programs could foster more

sustainable long-term outcomes and mitigate the high drop-out rates observed.

Discussion:

The study further advocates for integrating PMV monitoring into routine

clinical practice, allowing clinicians to personalize treatment plans based on individual

thromboembolic risk.

2025

APRIL

NEW RENAISSANCE

INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE

VOLUME 2

|

ISSUE 4

252

Elevated PMV levels indicate a heightened risk of adverse thromboembolic events, and

their routine monitoring could offer a cost-effective means to tailor anticoagulation therapy,

especially in high-risk groups. This approach aligns with global standards for precision medicine,

promoting individualized care pathways that optimize therapeutic efficacy while minimizing

unnecessary risks.

Overall, the findings underscore the critical need for a personalized, integrative approach

to CRD management, combining pharmacological therapies with innovative biomarker-based

assessments and comprehensive patient education. The incorporation of PMV analysis as a

predictive tool enables targeted therapeutic strategies, allowing healthcare providers to prioritize

high-risk patients and make informed decisions on anticoagulant regimens. This study contributes

valuable knowledge to the field of cardiovascular medicine, particularly in resource-limited

settings, by supporting PMVs as a viable biomarker for thromboembolic risk.

Conclusion:

This research lays the groundwork for future studies aimed at expanding the

understanding of PMVs’ role in thromboembolic risk and assessing the long-term benefits of

routine PMV monitoring. Additionally, the findings suggest avenues for improving adherence

strategies, which could include tailored education initiatives or interventions addressing specific

barriers to adherence, such as financial constraints. By validating these findings in larger, diverse

populations, future studies can build on this work to refine and expand personalized cardiovascular

care models, ultimately aiming to reduce thromboembolic complications and improve quality of

life for CRD patients both in Uzbekistan and globally.

REFERENCES

1.

Albert, M. A., & Ridker, P. M. (2004). Inflammatory biomarkers in African Americans: A

potential link to accelerated atherosclerosis and adverse cardiovascular outcomes. Journal of

the

American

College

of

Cardiology,

44(2),

347-355.

https://doi.org/10.1016/j.jacc.2004.03.053

2.

Armstrong, R. A. (2019). Risk factors for Alzheimer’s disease. Folia Neuropathologica,

57(2), 87-105.

3.

Badrnya, S., Baumgartner, R., & Assinger, A. (2014). Smoking alters circulating platelet-

derived

microvesicles.

Thrombosis

Research,

137(3),

452-457.

https://doi.org/10.1016/j.thromres.2014.12.022

2025

APRIL

NEW RENAISSANCE

INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE

VOLUME 2

|

ISSUE 4

253

4.

Cocco, G., & Jerie, P. (2015). Management of atrial fibrillation in patients with ischemic

heart disease. Heart Failure Reviews, 20(2), 141-159.

https://doi.org/10.1007/s10741-014-

9460-x

5.

Davi, G., & Patrono, C. (2007). Platelet activation and atherothrombosis. New England

Journal of Medicine, 357(24), 2482-2494. https://doi.org/10.1056/NEJMra071014

6.

Fahed, A. C., & Nemer, G. M. (2011). Microvesicles: Key players in cardiovascular

disorders. Cardiovascular Research, 90(1), 1-4. https://doi.org/10.1093/cvr/cvr017

7.

Heidbuchel, H., Verhamme, P., & Alings, M. (2013). Updated European Heart Rhythm

Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients

with

non-valvular

atrial

fibrillation.

Europace,

15(5),

625-651.

https://doi.org/10.1093/europace/eut083

8.

Jayaraman, S., & Kottke-Marchant, K. (2010). Role of platelets in inflammation and

thrombosis.

Thrombosis

Research,

125(5),

443-449.

https://doi.org/10.1016/j.thromres.2009.10.013

9.

Li, H., & He, C. (2020). Platelet microvesicles and cardiovascular diseases. Journal of

Biomedical Science, 27(1), 1-9. https://doi.org/10.1186/s12929-020-00666-7

10.

Lip, G. Y., & Lane, D. A. (2015). Stroke prevention in atrial fibrillation: A systematic

review. JAMA, 313(19), 1950-1962. https://doi.org/10.1001/jama.2015.4369

11.

Madsen, C., & Jørgensen, K. A. (2014). Platelet-derived microvesicles as predictive

biomarkers in cardiovascular disease: A systematic review and meta-analysis. Thrombosis

and Haemostasis, 111(6), 1106-1115. https://doi.org/10.1160/TH13-12-1021

12.

Ridker, P. M., & Cook, N. R. (2013). Reduction in C-reactive protein and ischemic events

in patients receiving rosuvastatin: The JUPITER trial. New England Journal of Medicine,

359(21), 2195-2207. https://doi.org/10.1056/NEJMoa0807646